Avoro Capital Advisors LLC Trims Stock Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Avoro Capital Advisors LLC lowered its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 19.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 9,910,642 shares of the company's stock after selling 2,435,036 shares during the quarter. Avoro Capital Advisors LLC owned about 3.72% of Autolus Therapeutics worth $23,290,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State Street Corp increased its holdings in Autolus Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 606,544 shares of the company's stock worth $2,202,000 after acquiring an additional 10,401 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Autolus Therapeutics by 145.3% during the third quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock worth $4,663,000 after purchasing an additional 761,008 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in shares of Autolus Therapeutics in the fourth quarter worth approximately $611,000. Avanza Fonder AB purchased a new stake in Autolus Therapeutics in the fourth quarter valued at approximately $75,000. Finally, Arkadios Wealth Advisors bought a new stake in Autolus Therapeutics during the fourth quarter valued at approximately $47,000. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Price Performance

AUTL traded down $0.07 on Friday, hitting $1.33. The company had a trading volume of 2,740,804 shares, compared to its average volume of 1,469,451. Autolus Therapeutics plc has a 52-week low of $1.11 and a 52-week high of $5.00. The stock has a fifty day simple moving average of $1.63 and a 200-day simple moving average of $2.47. The firm has a market capitalization of $353.91 million, a P/E ratio of -1.10 and a beta of 2.06.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million for the quarter, compared to analysts' expectations of $2.98 million. Equities research analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Needham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Truist Financial cut their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Wells Fargo & Company decreased their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a report on Friday, March 21st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $9.32.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.